Clinical trial
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients…
NCT02998879 · Chiesi Farmaceutici S.p.A., Industry · Completed
Key facts
| NCT number | NCT02998879 |
|---|---|
| Title | Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis |
| Official title | A 24-month Multicenter, Open-label Phase II Trial Investigating the Safety and Efficacy of Repeated Velmanase Alfa (Recombinant Human Alpha-mannosidase) Treatment in Pediatric Patients Below 6 Years of Age With Alpha-Mannosidosis |
| Acronym | rhLaman-08 |
| Lead sponsor | Chiesi Farmaceutici S.p.A., Industry |
| Collaborators | Cromsource Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alpha-Mannosidosis |
| Intervention type | Drug |
| Interventions | Velmanase Alfa (e.g. Lamazym) |
| Enrollment | 5 |
| Start date | Dec 1, 2016 |
| Primary completion | Jul 1, 2020 |
| Completion | Jul 1, 2020 |
| First posted | Dec 21, 2016 |
| Last update posted | Oct 26, 2021 |
| Countries | Austria, Denmark, France, Germany, Italy |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: